Oligometastatic prostate cancer: Jadvar provides an overview of this complex disease setting and recommends increased research and analytic foci on precise and optimal molecular imaging and clinical management techniques. *Page 1338*

Imaging cancer metabolism: Pantel and colleagues discuss the underlying biology of metabolic dysregulation in cancer, including glucose, glutamine, and acetate metabolism and associated imaging strategies. *Page 1340*

Covalent labels for PET: Pichler and colleagues offer an educational overview of the radiochemistry of PET tracers that exhibit a covalently bound radiolabel with ^{11}C, ^{13}N, and ^{18}F, including the tracer life cycle from radionuclide production through quality control. *Page 1350*

PET metallomics: Bartnicka and Blower report on the growing availability of positron-emitting isotopes of key essential metals, particularly ^{64}Cu, ^{63}Zn, and ^{52}Mn, that provide new tools with which to image disturbed metal homeostasis. *Page 1355*

SUV and tumor progression: Cornelis and colleagues investigate whether intraprocedural ^{18}F-FDG PET/CT can serve as a biomarker and predictor of local tumor progression after percutaneous ablation of colorectal liver metastases. *Page 1360*

SPECT/CT for lung shunt quantification: Dittmann and colleagues evaluate quantitative SPECT/CT for hepatopulmonary fraction assessment in a prospective clinical cohort scheduled to undergo selective internal radiotherapy for liver metastases. *Page 1366*

^{99m}Tc-PSMA vs ^{99m}Tc-MDP: Rathke and colleagues assess the rates of detection of bone metastases with these 2 tracers in patients with known advanced-stage osseous metastasized prostate cancer. *Page 1373*

^{18}F-Fludarabine for lymphoma imaging: Chantepie and colleagues describe a first-in-humans clinical study of ^{18}F-fludarabine PET in patients with diffuse large B-cell lymphoma or chronic lymphocytic leukemia. *Page 1380*

HER2-selective tyrosine kinase inhibitor: Tang and colleagues detail the development of a $^{125/131}$I-labeled agent targeting human epidermal growth factor receptor type 2 and evaluate it in HER2-positive and -negative subcutaneous human breast cancer xenografts. *Page 1386*

^{68}Ga-PSMA11 PET/CT in mice: Lückerath and colleagues explore the reproducibility of imaging signal and relationship between quantitative cell-surface prostate-specific membrane antigen expression and prostate cancer lesion detectability with this tracer in small animal PET/CT. *Page 1392*

Immuno-PET/NIRF in pancreatic cancer: Zettlitz and colleagues develop a dual-labeled probe based on A2 cys-diabody targeting of the cell-surface prostate stem cell antigen, with potential for both whole-body PET in pancreatic cancer and near-infrared fluorescence surgical guidance. *Page 1398*

PSMA ligand uptake in ganglia: Rischpler and colleagues explore physiologic prostate-specific membrane antigen ligand uptake on ^{68}Ga-PSMA-HBED-CC PET in cervical, celiac, and sacral ganglia of the sympathetic trunk as a confounding factor in imaging lymph node metastases in prostate cancer. *Page 1406*

Fibroblast-activating protein: Siveke offers perspective on the potential for therapeutic targeting of cancer-associated fibroblasts, a multifunctional and abundant cell population in tumor microenvironments, and previews 2 associated articles in this issue of *JNM*. *Page 1412*

Theranostic ligands for FAP: Lindner and colleagues research in preclinical studies and in preliminary human testing a radiolabeled fibroblast activation protein inhibitor with promise for imaging and targeted therapy of tumors with high activated fibroblast content, such as breast cancer. *Page 1415*

Imaging of activated fibroblasts: Loktev and colleagues describe an iodinated and a DOTA-coupled radiotracer based on a fibroblast activation protein–specific enzyme inhibitor and evaluate them in vitro and in tumor-bearing animals. *Page 1423*

Myocardial perfusion in Chagas disease: Oliveira and colleagues investigate the occurrence of myocardial perfusion defects and correlated regional changes to histology in an experimental hamster model of chronic Chagas cardiomyopathy. *Page 1430*

Metabolic pattern of iRBD: Meles and colleagues identify the ^{18}F-FDG PET metabolic pattern underlying idiopathic rapid eye movement sleep behavior disorder and compare it with the known Parkinson disease pattern. *Page 1437*

Age and 5-HT$_6$ receptors in men: Radhakrishnan and colleagues explore in healthy men the effects of age on 5-HT$_6$ receptor availability using ^{11}C-GSK215083, a PET ligand with affinity for 5-HT$_6$ in the striatum and 5-HT$_{2A}$ in the cortex. *Page 1445*

Fetal dosimetry in PET/CT: Xie and colleagues expand on previously developed computational phantoms for pregnant women and describe a personalized model for patient-specific radiation dose in a twin pregnancy. *Page 1451*

Imaging bystander payload distribution: Cilliers and Thurber offer perspective on antibody–drug conjugates, a promising class of therapeutics for molecular targeting, and preview an article in this *JNM* issue on dual-isotope tracking of both antibody and payload with these conjugates. *Page 1459*

CIQA for ADC intratumoral distribution: Ilovich and colleagues present a dual-isotope cryoimaging quantitative autoradiography methodology combined with 3D imaging and analysis for simultaneous study of both antibody and payload distribution of antibody–drug conjugates in tissue. *Page 1461*

Impact of PET/MR motion correction: Manber and colleagues test the ability of a PET/MR-based predictive model to correct PET respiratory motion and determine whether it can improve lesion detectability and quantitation and reduce image artifacts. *Page 1467*

PET/DCE-MR concurrent motion correction: Fuin and colleagues detail an approach for concurrent reconstruction of respiratory motion–compensated abdominal dynamic contrast-enhanced MR and PET imaging data in an integrated PET/MR scanner. *Page 1474*

PET/CT respiratory motion correction: Lu and colleagues establish a framework to address artifacts from mismatches between respiration-gated PET images and CT attenuation correction maps, as well as other limitations of current respiratory motion correction methods. *Page 1480*

JNM599tmi ■ 8/18/18